Japanese pharmaceutical giant Takeda announced complete discontinuation of its cell therapy research efforts after previously scaling back its work in this space. The company plans to seek external partners to advance prior cell therapy platforms and clinic-ready programs. This decision is part of a broader portfolio prioritization process emphasizing investments in biologics, small molecules, and antibody-drug conjugates with potential for transformative therapies. Takeda faces impairment charges related to its former gamma delta cell therapy assets and reframes its focus amid challenging funding and commercial environments for cell therapies.